ESTRO 2024 - Abstract Book

S2973

Interdiscplinary - Other

ESTRO 2024

1.The alfa and beta of tumours: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies C. M. van Leeuwen, A. L. Oei1, J. Crezee, A. Bel1, N. A. P. Franken, L. J. A. Stalpers and H. P. Kok. van Leeuwen et al. Radiation Oncology (2018) 13:96. https://doi.org/10.1186/s13014-018-1040-z 2. The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery John P. Kirkpatrick, J. Meyer, L. B. Marks, 2008 Semin Radiat Oncol 2008 Oct;18(4):240-3. doi: 10.1016/j.semradonc.2008.04.005. 3. Variability of α/β ratios for prostate cancer with the fractionation schedule: caution against using the linear quadratic model for hypofractionated radiotherapy Ming Cui, Xian-Shu Gao, Xiaoying Li, Mingwei Ma, Xin Qi1 and Yuta Shibamoto 2022. Cui et al. Radiation Oncology (2022) 17:54. https://doi.org/10.1186/s13014-022-02010-9 4. Randomized phase III nonin-feriority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. Lee WR, Dignam JJ, Amin MB, Bruner DW, Low D, Swanson GP, Shah AB, D’Souza DP, Michalski JM, Dayes IS, et al. J Clin Oncol. 2016;34(20):2325–32. J Clin Oncol 2016 Jul 10;34(20):2325-32. doi: 10.1200/JCO.2016.67.0448. 5. Acute and late toxicity in arandomized trial of conventional versus hypofractionated threedimensional conformal radiotherapy for prostate cancer. Arcangeli G, Fowler J, Gomellini S, et al. Int J Radiat Oncol Biol Phys. 2011;79:1013-1021. Int J Radiat Oncol Biol Phys. 2011 Mar 15;79(4):1013-21. doi: 10.1016/j.ijrobp.2009.12.045. Epub 2010 May 5. 6. Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415. Thor M, Deasy JO, Paulus R, et al. Radiother Oncol. 2019 Jun: 135:19-24. doi: 10.1016/j.radonc.2019.02.014. Epub 2019 Mar 5 7. Estimates of Alpha/Beta (a/b) Ratios for Individual Late Rectal Toxicity Endpoints: An Analysis of the CHHiP Trial. Douglas H. Brand, MRCP, Sarah C. Bru¨ningk, Anna Wilkins, FRCR, Katie Fernandez, M.Biochem, Olivia Naismith, MSc,k Annie Gao, MSc, Isabel Syndikus, David P. Dearnaley, Alison C. Tree, Nicholas van As, Emma Hall, and Sarah Gulliford, on behalf of the CHHiP Trial Management Group. Int J Radiat Oncol Biol Phys. 2021 Jun 1;110(2):596-608. doi: 0.1016/j.ijrobp.2020.12.041. Epub 2021 Jan 4. 8. The Fraction Size Sensitivity of Late Genitourinary Toxicity: Analysis of Alpha/Beta (a/b) Ratios in the CHHiP Trial. Douglas H. Brand, Sarah C. Bruningk, Anna Wilkins, Olivia Naismith, Annie Gao, Isabel Syndikus, David P. Dearnaley, Nicholas van As, Emma Hall, Sarah Gulliford, and Alison C. Tree, On behalf of the CHHiP Trial Management Group. Int J Radiat Oncol Biol Phys. 2023 Feb 1;115(2):327-336. doi: 10.1016/j.ijrobp.2022.08.030. Epub 2022 Aug 17. 9. An algorithm for thoracic re-irradiation using biologically efective dose: a common language on how to treat in a “no-treat zone”. Eric D. Brooks, Xiaochun Wang, Brian De, Vivek Verma, Tyler D. Williamson , Rachel Hunter , Abdallah S. R. Mohamed , Matthew S. Ning , Xiaodong Zhang and Joe Y. Chang. Brooks et al. Radiation Oncology (2022) 17:4 https://doi.org/10.1186/s13014-021-01977-1 10. Basic Clinical Radiobiology FOURTH EDITION Edited by Michael Joiner Professor of Radiobiology Wayne State University USA Albert van der Kogel Professor of Radiobiology Radboud University Nijmegen Medical Centre The Netherlands. http://www.hoddereducation.com © 2009 Edward Arnold